medigraphic.com

2014, Number 4

<< Back Next >>

Rev Mex Anest 2014; 37 (4)

Bemiparin in critical care obstetrics

Briones-Vega C, Viruez-Soto JA, Vallejo-Narváez CM, Nieto-Anaya NM, Briones-Garduño JC, Díaz-de León-Ponce MA

Language: Spanish
References: 17
Page: 266-270
PDF size: 206.91 Kb.


ABSTRACT

Background: Thromboembolism persists as a main cause of maternal mortality, even in developed countries. Bemiparin is a second generation low molecular weight heparin, with the lowest molecular weight, longest half life and highest activity anti-FXa/anti-FIIa ratio (8:1). The objective is describe the experience in thromboprofilaxis with bemiparin in the Critical Care Obstetrics Unit in Hospital General de México «Dr. Eduardo Liceaga» during period may 2-june 2 of 2014. Methods: All the patients (n = 25) received 3,500 UI of bemiparin per day, as non alternant-TED stockings. Results: The Wells and Geneva scores, at the admission as outcome dismiss thromboembolism, there were no deaths, nor adverse events associated to the administration of bemiparin. Conclussions: The pharmacological profile of bemiparin, suggests it as the first line drug in thromboprofilaxis in Critical Care Obstetrics patients.


REFERENCES

  1. Cruz M, Fernández-Alonso AM, Rodríguez I, Garrigosa L, Caño A, Carretero P, et al. Postcesarean thromboprophylaxis with two different regimens of bemiparin. Obst Gynecol Int. [revista en Internet]. 2011 [citado 18 noviembre 2014]; Article ID 548327: [alrededor de 6 páginas]. doi:10.1155/2011/548327 Disponible en: http://www.researchgate.net/publication/221744703_Postcesarean_thromboprophylaxis_with_two_different_regimens_of_bemiparin

  2. Bansal T, Jaiswal R, Hooda S. Anaesthetic considerations in a patient with deep vein thrombosis on warfarin for emergency surgery: a case report. The Indian Anaesthetists’ Forum. 2013;14:1-5.

  3. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106:401-407.

  4. Fontcuberta-Boj J. Nuevas fronteras para bemiparina. Drugs. 2010;70:43-47.

  5. Fernández-Pavón A. Farmacología de bemiparina. Emergencias. 2004;15:2-4.

  6. Duboscq C, Ceresetto J, Stemmelin G, Shanley C, Rabinovich O, Palmer S, Bullorsky EO. Efecto de las heparinas de bajo peso molecular (HBPM) de primera y segunda generación sobre la prueba de generación de trombina. Hematología. 2013;17:231-237.

  7. Alalaf A. Bemiparin versus low dose aspirin for management of recurrent pregnancy losses due to antiphospholipid antibody syndrome. Arch Gynecol Obstet. 2012;285:641-647.

  8. Alijotas-Reig J. Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus. 2013;22:6-17.

  9. Xiao J, Xiong J, Zhu F, He L. Effect of prednisone, aspirin, low molecular weight heparin and intravenous immunoglobulin on outcome of pregnancy in women with antiphospholipid syndrome. Exp Ther Med. 2013;5:287-291.

  10. Laddad MM, Kshirsagar NS, Patil SP, Shinde G, Nimbalkar P. Low dose aspirin in combination with low-molecular-weight heparin is better than low dose aspirin alone in the treatment of pregnant women with recurrent miscarriages. Journal of Evolution of Medical and Dental Sciences. 2014;3:5753-5760.

  11. Guven D, Bakay K, Kocak I, Ozdemir A. Effectiveness of bemiparin sodium for preventing pregnancy loss in patients with MTHFR C677T mutation and habitual abortus. Open Journal of Obstetrics and Gynecology. 2014;4:930-934.

  12. Dogan OT, Polat ZA, Karahan O, Epozturk K, Altun A, Akkurt I, et al. Antiangiogenic activities of bemiparin sodium, enoxaparin sodium, nadroparin calcium and tinzaparin sodium. Thromb Res. 2011;128:29-32.

  13. Briones GJC, Díaz de León PM, Irigoyen CL, Martínez BL, Briones VCG, Urrutia TF. Anticuerpos anticardiolipina en preeclampsia eclampsia. Rev Asoc Mex Med Crit y Ter Int. 1997;11:194-196.

  14. Briones GJC, Díaz de León PM, Barrios PE, Salazar EJD. Anticuerpo antifosfolípido IgM en preeclampsia-eclampsia. Cir Ciruj. 2003;71:449-454.

  15. Salazar EJD, Reyes MRI, González AR, Briones GJC. P-Selectina como marcador de reactividad endotelial en pacientes con preeclampsia-eclampsia. Cir Ciruj. 2004;72:121-124.

  16. Briones VCG, Meneses CJ, Moreno SA, Torres PJ, Mujica HM, Díaz de León PM, et al. Factor de Von Willebrand (FVW) y agregación plaquetaria en preeclampsia severa. Rev Asoc Mex Med Crit y Ter Int. 2006;20:164-167.

  17. Briones VCG, García CR, Briones GJC. Homocisteína y mutación C677T y A1298C del gen de la 5-Metiltetrahidrofolato reductasa en embarazadas con preeclampsia-eclampsia. Rev Asoc Mex Med Crit y Ter Int. 2007;21:179-184.




2020     |     www.medigraphic.com